Not really catalysts, but also important will be the price setting of generic renagel/renvela and the focus on FGF-23 as a (new?) therapeutic target, which might lead to different subpopulations to treat.
Also important: price setting by Impax Laboratories of generic renagel/renvela (often overlook in my opinion); meeting with the FDA on phase III NDD-CKD (which primary and secondary endpoints will they agree on?), partnership/(sub)licence agreement in Europe, role of FGF-23 as a possible new therapeutic target (new subpopulations to target?), update on the IP front.
I disagree. "Third-quarter sales of Renvela®/Renagel® reached €187 million, an increase of 20.7% driven by the U.S. where sales grew 20.9% to €132 million. The product also delivered double-digit sales growth in Emerging Markets and in Western Europe. Year-to-date sales of Renvela®/Renagel® totaled €533 million, up 15.3%." (Q3 2013 Marks the End of the Patent Cliff Period)
And if you extrapolate 3Q to the entire year and convert it to dollars, R/R is over 1B in sales.